CubicBio — A Texas
Longevity Company
CubicBio is an early-stage biomanufacturing research company developing advanced cell-based approaches to target the hallmarks of aging — with the long-term goal of extending healthspan and redefining what it means to grow older.
Who We Are
Built in Texas.
Focused on Longevity.
Based at BioLabs Dallas (3060 Pegasus Park Dr., Dallas, TX), CubicBio brings together process engineers, cell biologists, and longevity researchers united by one conviction: aging is not a fixed destination. The biology that drives it can be intervened upon with precision.
We are an early-stage research company — our programs are actively in development. We draw from Texas's deep research ecosystem while laying the scientific and manufacturing groundwork for the next generation of longevity interventions.
Mission
To extend human healthspan. We research and develop next-generation, cell-based longevity approaches — starting with autologous NK cells — with the long-term goal of making production accessible and decentralized.
Vision
A future where aging is a manageable process: where senescent cell burden can be reduced on schedule, immune function can be restored, and an extra decade of vitality is achievable for millions.
Approach
We sit at the intersection of process engineering and cutting-edge immunology. Our research focuses on closed-system, distributed biomanufacturing with the goal of enabling scalable personalized cell-based approaches.
Lead Research Program
Autologous NK Cell Research
Our lead program asks a simple question: can the body’s own Natural Killer (NK) cells — grown and activated outside the body — find and eliminate the senescent cells that drive age-related tissue damage? This work is in active research and development.
Blood Draw & Isolation
First, peripheral blood cells are collected via apheresis — a standard procedure that separates specific cell types from blood. We are developing protocols to isolate NK cells using closed-system separation, minimizing contamination risk and variability.
Expansion & Activation
Our research focuses on growing NK cells outside the body (ex vivo) in controlled bioreactors. We are optimizing activation protocols for one specific job: destroying senescent cells.
Quality Release
We are developing quality tests covering sterility, identity, potency, and viability — designed to meet future regulatory standards for therapies made from a patient’s own cells.
Reinfusion
The final step is reinfusion: returning the expanded NK cells to the patient. The hypothesis we are actively investigating is that they will clear senescent cells, which display NK-activating signals such as NKG2D.
Autologous Safety Hypothesis
Our approach uses the patient's own cells. We believe this could reduce immune rejection and graft-vs-host risk — the key scientific rationale for our autologous program.
Targeting Senescent Cells
Senescent cells — the "zombie cells" that accumulate with age — evade immune surveillance. Our research aims to develop NK cell protocols designed to restore that surveillance.
Process-First R&D
We engineer the manufacturing process itself, not just the biology — researching how to achieve consistent, scalable cell production that could support distributed sites in the future.
Interested in our research, collaborations, or following our scientific progress?
Get in TouchWhat We Do
Our Research Focus Areas
Three interconnected research areas that together define CubicBio’s approach to the longevity landscape — all currently in active development.
Cell Production R&D
Biomanufacturing
We are developing closed-system bioreactor workflows that grow a patient’s own cells. Our process-first mindset means every step is engineered for reproducibility, yield, and future regulatory traceability.
- Closed-system expansion protocols
- GMP-grade process design
- In-process analytics research
- Process development & optimization
Future Production Vision
Decentralized Manufacturing
Today, cell therapies are made in large central facilities — a bottleneck. We are researching distributed manufacturing models that could remove it. Our long-term goal is production at or near the point of care, shortening the time from cell collection to reinfusion.
- Automated closed-system cell processing
- Site qualification frameworks
- Supply chain research
- Multi-site regulatory strategy
Translational Science
R&D Programs
Our pipeline connects academic longevity science to future clinical use — identifying the protocols, biomarkers, and manufacturing parameters that could define the next generation of longevity interventions.
- NK cell activation optimization
- Senescence biomarker development
- Protocol design for clinical pilots
- Academic & TMC collaborations
Research Hub
The Science of Longevity
Curated papers and clinical trials in NK cell biology, cellular senescence, and longevity science. Use this as your launchpad into the field.
Hallmarks of Aging: An Expanding Universe
López-Otín C, et al. — Cell, 2023
A landmark update to the original 2013 paper, expanding the hallmarks of aging to twelve, including disabled macroautophagy, chronic inflammation, and dysbiosis. Essential reading for anyone working in longevity science.
Clearance of Senescent Cells by ABT263 Rejuvenates Aged Hematopoietic Stem Cells in Mice
Chang J, et al. — Nature Medicine, 2016
Demonstrates that pharmacological clearance of senescent cells using the senolytic ABT263 restores hematopoietic stem cell function in aged mice — a pivotal proof-of-concept for senolytic therapy.
First-in-Human Pilot Trial of Senolytics (Dasatinib + Quercetin) in Diabetic Kidney Disease
Kirkland JL, et al. — EBioMedicine, 2019
The first clinical evidence that senolytic drugs can reduce senescent cell burden in humans. Subjects treated with dasatinib and quercetin showed decreased senescent cells in adipose tissue and improved physical function.
Natural Killer Cell Immunotherapy for Cancer: From Discovery to Clinical Application
Shimasaki N, et al. — Nature Reviews Drug Discovery, 2020
Comprehensive review of NK cell biology, manufacturing strategies, and clinical translation. Covers autologous and allogeneic approaches, expansion protocols, and the evolving landscape of NK-based immunotherapy.
NK Cell–Based Immunotherapy for Malignant Diseases: From Bench to Bedside (NCT03019640)
ClinicalTrials.gov — ClinicalTrials.gov, 2022
Phase I/II trial evaluating the safety and efficacy of autologous NK cell infusions in patients with advanced solid tumors. Assessing expansion protocols, infusion schedules, and biomarkers of response.
NK Cells in Age-Related Inflammation: Implications for Immunosenescence and Longevity
Hazeldine J & Lord JM — Ageing Research Reviews, 2021
Details how NK cell function declines with age — including reduced cytotoxicity and altered receptor expression — and explores how restoring NK cell activity may mitigate inflammaging and extend healthspan.
Decentralized Manufacturing of Cell and Gene Therapies: Overcoming Challenges and Uncertainties
Harrison RP, et al. — Cytotherapy, 2019
Analyzes how distributed, point-of-care biomanufacturing models can democratize access to cell therapies, reduce cold-chain costs, and enable faster vein-to-vein times for autologous products.
Senescent Cells: An Emerging Target for Diseases of Aging
Kirkland JL & Tchkonia T — Cell, 2017
A key mechanistic review establishing that senescent cells secrete the SASP (senescence-associated secretory phenotype), driving tissue dysfunction and age-related disease, making them a compelling therapeutic target.
NAD+ Metabolism and Its Roles in Cellular Processes During Ageing
Covarrubias AJ, et al. — Nature Reviews Molecular Cell Biology, 2021
Reviews the critical decline of NAD+ with age and how supplementation with precursors (NMN, NR) can restore mitochondrial function, DNA repair, and cellular resilience — a foundation of modern longevity interventions.
CAR-NK Cells vs CAR-T Cells: Advantages of Off-the-Shelf Manufacturing
Liu E, et al. — New England Journal of Medicine, 2020
Reports the first successful use of allogeneic, cord-blood–derived CAR-NK cells in patients with relapsed/refractory lymphoma — demonstrating that NK cells can be banked and delivered without the manufacturing delays of autologous T-cell products.
Research cards link to peer-reviewed publications and registered clinical trials. CubicBio does not author or control third-party content.
Did You Know?
Longevity Curiosities
Science doesn't have to be inaccessible. Here are five fascinating facts about how aging works — and why it matters.
The Oldest Human Lived to 122
Jeanne Calment of France lived to 122 years and 164 days — the oldest verified human lifespan on record. Researchers study genetic and lifestyle factors in supercentenarians to understand what drives extreme longevity.
Senescent Cells Accumulate Over Time
As we age, damaged cells that refuse to die accumulate in our tissues. These "zombie cells" secrete inflammatory signals (the SASP) that degrade surrounding tissue — and are now a primary therapeutic target in longevity research.
Blue Zones Share 5 Lifestyle Traits
People in Blue Zones (Okinawa, Sardinia, Loma Linda, Nicoya, Ikaria) share natural movement, a sense of purpose (ikigai), stress-reduction practices, plant-based diets, and strong social belonging — all independently linked to longer healthspan.
Your NAD+ Levels Drop ~50% by Midlife
NAD+ is a coenzyme essential for energy metabolism and DNA repair. By age 50, cellular NAD+ levels can fall to half of youthful levels — contributing to mitochondrial dysfunction, cognitive decline, and reduced cellular resilience.
NK Cells Are the Immune System's First Responders
Natural Killer cells patrol the body continuously, eliminating virus-infected and cancerous cells without prior sensitization. Their activity declines with age — and restoring their function is an emerging strategy to fight both cancer and cellular aging.
Common Questions
Frequently Asked Questions
Straight answers about our science, our process, and where we are on the path from research to reality.
What is CubicBio?
CubicBio is an early-stage longevity biotech based at BioLabs Dallas, Texas. We research autologous NK (natural killer) cell therapies and decentralized biomanufacturing processes, with the goal of extending human healthspan by clearing senescent cells — the "zombie cells" that accumulate with age.
How does CubicBio's NK cell approach work?
Our lead program follows four steps: collection of the patient's peripheral blood cells via apheresis, isolation of NK cells using closed-system separation, expansion and activation ex vivo in controlled bioreactor environments, and reinfusion. The goal is for re-infused NK cells to identify and eliminate senescent cells expressing activating ligands such as NKG2D. This work is in active R&D.
What are senescent "zombie cells," and why target them?
Senescent cells are damaged cells that stop dividing but refuse to die. They accumulate with age, secrete inflammatory signals, and drive aging-related tissue dysfunction. They also evade normal immune surveillance. Our research aims to restore that surveillance using the body's own natural killer cells.
What does "autologous" mean, and why does it matter?
Autologous means the cells come from the same patient who receives them. Our approach is designed around a patient's own cells, which we believe could reduce graft-vs-host risk and immune rejection compared with donor-derived cell therapies.
Is CubicBio's therapy available to patients?
Not at this time — our programs are in active research and development and have not entered clinical trials. CubicBio is a biomanufacturing research company, not a clinic, and we will not sell or administer treatments directly. Longer term, several U.S. states have legal pathways for physician-administered autologous cell therapies, and our decentralized manufacturing research is designed to support partners operating within those frameworks. Any broadly available therapy would require clinical trials and regulatory approval.
What is decentralized biomanufacturing?
Traditional cell therapy manufacturing happens in large centralized facilities. We research closed-system, distributed production processes so personalized cell therapies could one day be manufactured consistently at many smaller sites — improving access and reducing cost.
Contact
Let's Start a Conversation
Whether you're a researcher, clinician, investor, or someone curious about longevity therapies — we'd love to hear from you. We are actively building partnerships in Texas and beyond.